Drugs / XVR011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04884295 | Aug 2021 → Mar 2022 | COVID-19 | ExeVir Bio BV | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-10-20 | ExeVir Bio BV | Results ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors exevir.com ↗
The compound showed good pharmacodynamics and efficient GMP manufacturability. |
| 2021-07-13 | ExeVir Bio BV | Results ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern exevir.com ↗
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has generated data on its COVID-19 antibody XVR011 which demonstrate in vitro neutralization activity against SARS-CoV-2 Variants of Concern Gamma and Delta. |
| 2021-03-09 | ExeVir Bio BV | Results ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection against SARS-COV-2 and related coronaviruses exevir.com ↗
ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection against SARS-COV-2 and related coronaviruses |
All press releases naming this drug 4 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XVR011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04884295 ↗ |
| Route | Intravenous | “via intravenous (IV) infusion” NCT04884295 ↗ |